Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.

David M O'MalleyMaryna NeffaBradley J Monk Tamar MelkadzeMarilyn HuangAnna KryzhanivskaIurie BulatTarek M MeniawyAndrea BagameriEdward W WangBernard Doger de Speville UribeRoberto HeggWaldo Ortuzar FeliuMarek AncukiewiczIwona Lugowska

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Promising and durable clinical activity, with favorable tolerability, was seen in this largest trial to date evaluating dual programmed death-1/cytotoxic T-lymphocyte-associated antigen-4 blockade in patients with recurrent and/or metastatic cervical cancer. Further investigation of the balstilimab and zalifrelimab combination in this setting is continuing.

Keyphrases

phase ii study
open label
phase iii
phase ii
clinical trial
squamous cell carcinoma
study protocol
placebo controlled
locally advanced
small cell lung cancer
dna damage
cell cycle
randomized controlled trial
peripheral blood
cell proliferation
oxidative stress
radiation therapy